Recent advances in the synthesis of antischistosomal drugs and agents

Mini-Reviews in Medicinal Chemistry

Volumn 17, Issue 5, 2017, Pages 467-484

  Liu, Liang Xian ^a   Li Li, Jiang ^a   Qiong, Chang ^a   Xiao Lin, Fan ^a  

^a GANNAN NORMAL UNIVERSITY   (China)

Author keywords

Antischistosomal drugs; Chemotherapy; Praziquantel; Schistosomiasis

Indexed keywords

10 [2 (DIETHYLAMINO)ETHYL] 9(10H) ACRIDINONE (2 THIAZOLIDINYLIDENE)HYDRAZONE; 8 HYDROXYQUINOLINE-5 SUFONYL 1,4 DIAZEPINE DERIVATIVE; ANTHELMINTIC AGENT; ANTISCHISTOSOMAL AGENT; ARTEMISININ DERIVATIVE; BETULIC ACID; BETULIN; FUROXAN DERIVATIVE; MECLONAZEPAM; MEFLOQUINE; MILTEFOSINE; MMV 665852; OXAMNIQ; PRAZIQUANTEL; PYRIMIDINEDIONE DERIVATIVE; PYRROLO [1,2,5] BENZOTHIADIAZEPINE DERIVAVTIVE; TRIOXAQUANTEL; TRIPHENYLPHOSPHONIUM DERIVATIVE; UNCLASSIFIED DRUG;

ANTIPROTOZOAL ACTIVITY; APOPTOSIS; CHEMOPROPHYLAXIS; DRUG SYNTHESIS; HUMAN; IC50; METABOLITE; NONHUMAN; OPTICAL ROTATION; PARASITE TRANSMISSION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SCHISTOSOMIASIS; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; SCHISTOSOMA; SYNTHESIS;

ANIMALS; HUMANS; MOLECULAR STRUCTURE; SCHISTOSOMA; SCHISTOSOMIASIS; SCHISTOSOMICIDES;

EID: 85013876354     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557513666131119204558     Document Type: Review

References (119)

1. El-Lakkany, N.; Nosseir, M. Pharmacodynamics of pentoxifylline and/or praziquantel in murine schistosomiasis mansoni. APMIS, 2007, 115, 184-94.
2. Brightman, C. Schistosomiasis. Trends Urol Men’s Health, 2011, 2, 38-42.
3. Steinmann, P.; Keiser, J.; Bos, R.; Tanner, M.; Utzinger, J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect. Dis., 2006, 6, 411-25.
4. Bennett, J.E.; Dolin, R.; Blaser, M.J. Principles and practice of infectious diseases. Academic Press: Elsevier Saunders, 2015, 3199-3207.
5. Sayed, A.A.; Simeonov, A.; Thomas, C.J.; Inglese, J.; Austin, C.P; Williams, D.L. Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nat. Med., 2008, 14, 407-12.
6. Chitsulo, L.; Engles, D.; Montresor, A.; Savioli, L. The global status of schistosomiasis and its control. Acta Trop., 2000, 77, 41-51.
7. Chen, X.Y.; Wang, L.Y.; Cai, J.M.; Zhou, X.N.; Zheng, J.; Guo, J.G.; Wu, X.H.; Engeles, D.; Chen, M.G. Schistosomiasis control in China: the impact of a 10-year World Bank Loan Project (1992-2001). Bull. WHO, 2005, 83, 43-8.
8. Ross, A.G.; Bartley, P.B.; Sleigh, A.C.; Olds, G.R.; Li, Y.; Williams, G.M.; McManus, D.P. Schistosomiasis. N. Engl. J. Med., 2002, 346, 1212-20.
9. Christopherson, J.B.; Cantab, M.D.; Lond, F.R.C.P.; Eng, F.R.C.S. The successful use of antimony in bilharziosis. Lancet, 1918, 192, 325-327.
10. Bergquist, N.R. Schistosomiasis: from risk assessment to control. Trends Parasitol., 2002, 18, 309-14.
11. Yang, Z.S.; Wu, W.M.; Li, Y.; Wu, Y.L. Design and synthesis of novel artemisinin-like ozonides with antischistosomal activity. Helvetica Chimica Acta, 2005, 88, 2865-72.
12. Redman, C.A.; Robertson, A.; Fallon, P.G.; Modha, J.; Kusel, J.R.; Doenhoff, M.J.; Martin, R. Praziquantel: an urgent and exciting challenge. Parasitol. Today, 1996, 12, 14-20.
13. Abdul-Ghani, R.A.; Loutfy, N.; Sahn, A.E.; Hassan, A. Current chemotherapy arsenal for schistosomiasis mansoni: alternatives and challenges. Parasitol. Res., 2009, 104, 955-65.
14. Abdul-Ghani, R.A.; Loutfy, N.; Sahn, A.E.; Hassan, A. Experimentally promising antischistosomal drugs: a review of some drug candidates not reaching the clinical use. Parasitol. Res., 2009, 105, 899-906.
15. Olsen, A. Efficacy and safety of drug combinations in the treatment of schistosomiasis, soil-transmitted helminthiasis, lymphatic filariasis and onchocerciasis. Transact. Royal Soc. Trop. Med. Hygiene, 2007, 101, 747-58.
16. Ribeiro-dos-Santos, G.; Verjovski-Almeida, S.; Leite, L.C.C. Schistosomiasis-a century searching for chemotherapeutic drugs. Parasitol. Res., 2006, 99, 505-21.
17. Capron, A. Schistosomiasis: forty years’war on the worm, Parasitol. Today, 1998, 14, 379-436.
18. Cioli, D. Chemotherapy of schistosomiasis: an update. Parasitol. Today, 1998, 14, 418-22.
19. Sophie, A.L.; Thetiot L.; Jerome, B.; Anne, R.; Bernard, M. Schistosomiasis chemotherapy. Angew. Chem. Int. Ed., 2013, 52, 7936-7956.
20. Cioli, D.; Pica-Mattoccia, L.; Basso, A.; Guidi, A. Schistosomiasis control: praziquantel forever? Mol. Biochem. Parasitol., 2014, 195, 23-29.
21. de Moraes, J. Natural products with antischistosomal activity. Future Med. Chem., 2015, 7, 801-820.
22. Domling, A.; Khoury, K. Praziquantel and schistosomiasis, Chem. Med. Chem., 2010, 5, 1420-34.
23. Risi, C.D.; Pela, M.; Pollini, G.P.; Trapella, C.; Zanirato, V. Mastering chiral substituted 2-oxopiperazines. Tetrahedron: Asymmetry, 2010, 21, 255-74.
24. Seubert, J.; Pohlke, R.; Loebich, F. Enantioselective synthesis of praziquantel. Experientia, 1977, 33, 1036-7.
25. Frehel, D.; Marand, J.P. 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino [2,1-a]isoquinolin-4-one. Heterocycles, 1983, 20, 1731-5.
26. Berkowitz, W.F.; John, T.V. An internal imino-Diels-Alder route to a tetrahydroisoquinoline. J. Org. Chem., 1984, 49, 5269-71.
27. Yuste, F.; Pallas, Y.; Barrios, H.; Ortiz, B.; Sanchez-Obregon, R. A short synthesis of praziquantel. J. Heterocycl. Chem., 1986, 23, 189-90.
28. Novaes, M.R.C.G.; de Souza, J.P.; de Araujo, H.C. Sintese do anti-helmintico praziquantel, a partir da glicina. Quím. Nova, 1999, 22, 5-10.
29. Kim, J.H.; Lee, Y.S.; Kim, C.S. Synthesis of praziquantel via N-acyliminium ion cyclization of amido acetals through several synthetic routes. Heterocycles, 1998, 48, 2279-85.
30. Lim, B.G.; Ching, C.B. Characterization of chiral adsorbents on the chromatographic separation of praziquantel enantiomers. Ind. Eng. Chem. Res., 1996, 35, 169-75.
31. Pohlke, R.; Loebich, F.; Serbert, J.; Thomas, H.; Andrews, P. Pyrazinoisochinolin-derivat. German Patent 2,331, 713, January 23, 1975.
32. Kim, J.H.; Lee, Y.S.; Park, H.; Kim, C.S. Formation of pyrazinoisoquinoline ring system by the Tandem amidoalkylation and N-acyliminium ion cyclization: an efficient synthesis of praziquantel. Tetrahedron, 1998, 54, 7395-400.
33. Roszkowski, P.; Maurin, J.K.; Czarnocki, Z. Enantioselective synthesis of (R)-(-)-praziquantel (PZQ). Tetrahedron: Asymmetry, 2006, 17, 1415-9.
34. Ma, C.; Zhang, Q.F.; Tan, Y.B.; Wang, L. Total synthesis of (-)-praziquantel: an anthelmintic drug. J. Chem. Res., 2004, 186-7.
35. El-Fayyoumy, S.; Mansour, W.; Todd, M.H. Solid phase synthesis of praziquantel. Tetrahedron Lett., 2006, 47, 1287-90.
36. Todd, M.H.; Ndubaku, C.; Bartlett, P.A. Amino acid derived heterocycles: Lewis acid catalyzed and radical cyclizations from peptide acetals. J. Org. Chem., 2002, 67, 3985-8.
37. Brewer, M.D.; Burgess, M.N.; Dorgan, R.J.J.; Elliott, R.L.; Mamalis, P.; Manger, B.R.; Webste, R.A.B. Synthesis and anthelmintic activity of a series of pyrazino[2,l-a][2]benzazepine derivatives. J. Med. Chem., 1989, 32, 2058-62.
38. Hassanein, H.H.; El Nahal, H.M.; Gerges, F.R. Synthesis of some non-antimonial compounds bioisosteric to praziquantel. Eur. J. Med. Chem., 1995, 30, 525-9.
39. Ronketti, F.; Ramana, A.V.; Xia, C.M.; Pica-Mattoccia, L.; Cioli, D.; Todd, M.H. Praziquantel derivatives I: modification of the aromatic ring. Bioorg. Med. Chem. Lett., 2007, 17, 4154-7.
40. Dong, Y.X.; Chollet, J.; Vargas, M.; Mansour, N.R.; Bickle, Q.; Alnouti, Y.; Huang, J.G.; Keiser, J.; Vennerstrom, J.L. Praziquantel analogs with activity against juvenile Schistosoma mansoni. Bioorg. Med. Chem. Lett., 2010, 20, 2481-4.
41. Duan, W.W.; Qiu, S.J.; Zhao, Y.; Sun, H.; Qiao, C.H.; Xia, C.M. Praziquantel derivatives exhibit activity against both juvenile and adult Schistosoma japonicum. Bioorg. Med. Chem. Lett., 2012, 22, 1587-90.
42. Sadhu, P.S.; Kumar, S.N.; Chandrasekharam, M.; Pica-Mattoccia, L.; Cioli, D.; Rao, V.J. Synthesis of new praziquantel analogues: potential candidates for the treatment of schistosomiasis. Bioorg. Med. Chem. Lett., 2012, 22, 1103-6.
43. Laurent, S.A.L.; Boissie, J.; Coslédan, F.; Gornitzka, H.; Robert, A.; Meunier, B. Synthesis of “Trioxaquantel”R derivatives as potential new antischistosomal drugs. Eur. J. Org. Chem., 2008, 895-913.
44. Portela, J.; Boissier, J.; Gourbal, B.; Pradines, V.; Colliére, V.; Coslédan, F.; Meunier, B.; Robert, A. Antischistosomal activity of trioxaquines: in vivo efficacy and mechanism of action on Schistosoma mansoni. PloS Negl. Trop. Dis., 2012, 6, e1474. doi:10.1371/journalpntd 0001474.
45. Boissier, J.; Portela, J.; Pradines, V.; Coslédan, F.; Robert, A.; Meunier, B. Activity of trioxaquine PA1259 in mice infected by Schistosoma mansoni. Comptes Rendus Chimie, 2012, 15, 75-8.
46. Boissier, J.; Cosledan, F.; Robert, A.; Meunier, B. In vitro activities of trioxaquines against Schistosoma mansoni. Antimicrob. Agents Chemother., 2009, 53, 4903-6.
47. Cowan, N.; Yaremenko, I.A.; Krylov, I.B.; Terent’ev, A.O.; Keiser, J. Elucidation of the in vitro and in vivo activities of bridged 1,2,4-trioxolanes, bridged 1,2,4,5-tetraoxanes, tricyclic monoperoxides, silyl peroxides, and hydroxylamine derivatives against Schistosoma mansoni. Bioorg. Med. Chem., 2015, 23, 5175-5181.
48. Ingram, K.; Yaremenko, I.A.; Krylov, I.B.; Hofer, L.; Terent’ev, A.O.; Keiser, J. Identification of antischistosomal leads by evaluating bridged 1,2,4,5-tetraoxanes, alphaperoxides, and tricyclic monoperoxides. J. Med. Chem., 2012, 55, 8700-8711.
49. Richards, H.C.; Foster, R. A new series of 2-aminomethyltetrahydroquinoline derivatives displaying schistosomicidal activity in rodents and primates. Nature, 1969, 222, 581-2.
50. Fenwick, A.; Savioli, L.; Engels, D.; Bergquist, N.R.; Todd, M.H. Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends Parasitol., 2003, 19, 509-15.
51. Sabah, A.A.; Fletcher, C.; Webbe, G.; Doenhoff, M.J. Schistosoma mansoni: chemotherapy of infections of different ages. Exp. Parasitol., 1986, 61, 294-303.
52. Archer, S.; Yarinsky, A. Recent developments in the chemotherapy of schistosomiasis. Prog. Drug Res. 1972, 16, 11-66.
53. Appleton, C.C.; Mbaye, A. Praziquantel-quality, dosages and markers of resistance. Trends Parasitol., 2001, 17, 356.
54. Xiao, S.H.; Catto, B.A. Invitro and in vivo studies of the effect of artemether on Schistosoma mansoni. Antimicrob. Agents Chemother., 1989, 33, 1557-62.
55. Yang, Z.S.; Wu, W.M.; Li, Y.; Wu, Y.L. Design and synthesis of novel artemisinin–like ozonides with antischistosomal activity. Helv. Chem. Acta, 2005, 88, 2865-72.
56. Li, H.J.; Wang, W.; Qu, G.L.; Li, Y.Z.; Tao, Y.H.; Xing, Y.T.; Wang, X.T.; Dai, Y.; Wei, J.Y.; Dai, J.R.; Coles, G.C.; Liang, Y.S. Effect of the in vivo activity of dihydroartemisinin against Schistosoma mansoni infection in mice. Parasitol. Res., 2012, 110, 1727-32.
57. Liu, R.; Dong, H.F.; Zhao, Q.P.; Jiang, M.S. Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysis. Parasites Vectors, 2011, 4, 201-18.
58. Arsenault, P.R.; Wobbe, K.K.; Weathers, P.J. Recent advances in artemisinin production through heterologous expression. Curr. Med. Chem., 2008, 15, 2886-96.
59. Levesque, F.; Seeberger, P.H. Continuousflow synthesis of the anti-malaria drug artemisinin. Angew. Chem. Int. Ed., 2012, 51, 1706-9.
60. Xiao, S.H.; Mei, J.Y.; Jiao, P.Y. Schistosoma japonicuminfected hamsters (Mesocricetus auratus) used as a model in experimental chemotherapy with praziquantel, artemether, and OZ compounds. Parasitol. Res., 2011, 108, 431-7.
61. Liu, R.; Dong, H.F.; Jiang, M.S. Artemisinin: the gifts from traditional Chinese medicine not only for malaria control but also for schistosomiasis control. Parasitol. Res., 2012, 110, 2071-4.
62. Le, W.J.; You, J.Q.; Mei, J.Y. Chemotherapeutic effect of artesunate in experimental schistosomiasis. Acta Pharmaceut. Sin., 1983, 18, 619-21 (in Chinese).
63. Xiao, S.H.; Tanner, M.; N’Goran, E.K.; Utzinger, J.; Chollet, J.; Bergquist, R.; Chen, M.G.; Zheng, J. Recent investigations of artemether, a novel agent for the prevention of Schistosomiasis japonica, mansoni and haematobia. Acta Trop., 2002, 82, 175-81.
64. Abdul-Ghani, R.; Loutfy, N.; Sheta, M.; Hassan, A. Artemether shows promising female schistosomicidal and ovicidal effects on the Egyptian strain of Schistosoma mansoni after maturity of infection. Parasitol. Res., 2011, 108, 1199-205.
65. Utzinger, J.; Xiao, S.H.; N’Goran, E.K.; Bergquist, R.; Tanner, M. The potential of artemether for the control of schistosomiasis. Int. J. Parasitol., 2001, 31, 1549-62.
66. Jiraungkoorsku, W.; Sahaphong, S.; Sobhon, P.; Riengrojpitak, S.; Kang-wanrangsan, N. The in vitro effect of praziquantel and artesunate on the adult fluke. Exp. Parasitol., 2006, 113, 16-23.
67. Manneck, T.; Haggenmller, Y.; Keiser, J. Morphological effects and tegumental alterations induced by mefloquine on schistosomula and adult flukes of Schistosoma mansoni. Parasitology, 2010, 137, 85-98.
68. Van Nassauw, L.; Toovey, S.; Op, V.; den Busch, J.; Timmermans, J.P.; Vercruysse, J. Schistosomicidal activity of the antimalarial drug, mefloquine, in Schistosoma mansoni-infected mice. Travel Med. Infect. Dis., 2008, 6, 253-8.
69. Keiser, J.; Chollet, J.; Xiao, S.H.; Mei, J.Y.; Jiao, P.Y.; Utzinger, J.; Tanner, M. Mefloquine-an aminoalcohol with promising antischistosomal properties in mice. PloS Neglected Tropical Diseases, 2009, 3, e350. doi:10.1371/journal.pntd.0000350.
70. Xiao, S.H.; Xue, J.; Zhang, H.B. Further studies on mefloquine and praziquantel alone or interaction of both drugs against Schistosoma japonicum in vitro. Parasitol. Res., 2012, 110, 1239-48.
71. Xiao, S.H.; Sun, J.; Xue, J.; Du, X.L.; Zhang, H.B. Ultrastructural alterations of juvenile Schistosoma japonicum harbored in mice following mefloquine administration. Parasitol. Res., 2012, 110, 637-44.
72. Zhang, C.W.; Xiao, S.H. Histopathological changes of juvenile Schistosoma japonicum harbored in mice treated orally with mefloquine at a smaller single dose. Parasitol. Res., 2012, 110, 2281-8.
73. Ohnmacht, C.J.; Patel, A.R.; Lutz, R.E. Antimalarials. 7. bis(trifluoromethyl)-α-(2-piperidyl)-4-quinolinemethanols. J. Med. Chem., 1971, 14, 926-8.
74. Brombacher, U.; Link, H.; Montavon, M. Schistosomicidal acridanone hydrazones. U.S. Patent 4,771,889, December 8, 1987.
75. Pax, R.; Bennett, J.L.; Fetterer, R. A benzodiazepine derivative and praziquantel: effects on musculature of Schistosoma mansoni and Schistosoma japonicum. Naunyn Schmiedebergs Arch. Pharmacol., 1978, 304, 309-15.
76. Cassal, J.M. Benzodiazepine derivatives and their pharmaceutical use. U.S. Patent 4,474,777, December 2, 1984.
77. Mahajan, A.; Kumar, V.; Mansour, N.R.N.; Bickle, Q.; Chibale, K. Meclonazepam analogues as potential new antihelmintic agents. Bioorg. Med. Chem. Lett., 2008, 18, 2333-6.
78. Menezes, C.M.S.; Rivera, G.; Alves, M.A.; do Amara, D.N.; Thibaut, J.P.B.; Noël, F.; Barreiro, E J.; Lima, L.M. Synthesis, biological evaluation, and structure-activity relationship of clonazepam meclonazepam, and 1,4-benzodiazepine compounds with schistosomicidal activity. Chem. Biol. Drug. Des., 2012, 79, 943-9.
79. Chen, J.L.; Sun, W.Z.; Yang, J.J.; Sun, H.; Wang, Z.X.; Dong, L.L.; Qiao, C.H.; Xia, C.M. Development of a novel class of pyrrolo-[1,2,5]benzothiadiazepine derivatives as potential antischistosomal agents. Bioorg. Med. Chem. Lett., 2013, 23, 3785-3787.
80. Raafat, S.; Nibal, A.H. Synthesis of new mercaptotriazoles with potential antibilharzial activity. J. Pharm. Sci., 1979, 68, 1377-1381.
81. Soliman, R.; Mokhtar, H.M.; el Sadany, S.K. Synthesis of new 8-(5-Substituted amino-1,3,4-oxadiazol-2-yl) and 8-(5-substituted amino-1,3,4-thiadiazol-2-yl) methoxyquinolines with antibilharzial activity. J. Pharm. Sci., 1984, 73, 403-405.
82. Eweas, A.F.; Allam, G.; Abuelsaad, A.S.A.; ALGhamd, A.H.; Maghrabi, I.A. Design, synthesis, anti-schistosomal activity and molecular docking of novel8-hydroxyquinoline-5-sulfonyl 1,4-diazepine derivatives. Bioorg. Chem., 2013, 46, 17-25.
83. Gasco, A.; Boulton, A.J. Furoxans and benzofuroxans. Adv. Heterocycl. Chem., 1981, 29, 251-340.
84. Feelisch, M.; Schonafinger, K.; Noack, E. Thiol-mediated generation of nitric oxide accounts for the vasodilator action of furoxans. Biochem. Pharmacol., 1992, 44, 1149-57.
85. Medana, C.; Ermondi, G.; Fruttero, R.; DiStilo, A.; Ferretti, C.; Gasco, A. Furoxans as nitric oxide donors. 4-Phenyl-3-furoxan carbonitrile: thiol-mediated nitric oxide release and biological evaluation. J. Med. Chem., 1994, 37, 4412-6.
86. Sorba, G.; Medana, C.; Fruttero, R.; Cena, C.; DiStilo, A.; Galli, U.; Gasco, A. Water soluble furoxan derivatives as NO prodrugs. J. Med. Chem., 1997, 40, 463-9.
87. Rai, G.; Thomas, C. J.; Leister, W.; Maloney, D. J. Synthesis of oxadiazole-2-oxide analogues as potential antischistosomal agents. Tetrahedron Lett., 2009, 50, 1710-3.
88. Thomas, C.J.; Maloney, D.J. Bantukallu, G.R.; Sayed, A.A.; Simeonov, A.; Williamas, D.L. Oxadiazole-2-oxides as antischistosomal agents. European Patent 2,310,378, April 20, 2011.
89. Nirode, W.F.; Luis, J.M.; Wicker, J.F.; Wachter, N.M. Synthesis and evaluation of NO-release from symmetrically substituted furoxans. Bioorg. Med. Chem., 2006, 16, 2299-301.
90. Kitahara, K.; Toma, T.; Shimokawa, J.; Fukuyama, T. O-TBS-Ntosylhydroxylamine: a reagent for facile conversion of alcohols to oximes. Org. Lett., 2008, 10, 2259-61.
91. Simeonov, A.; Jadhav, A.; Sayed, A.A.; Wang, Y.H.; Nelson, M.E.; Thomas, C.J.; Inglese, J.; Williams, D.L.; Austin, C.P. Quantitative high-throughput screen identifies inhibitors of the Schistosoma mansoni redox cascade. PloS Neglected Trop. Dis., 2008, 2, e127. doi: 10.1371/journal.pntd.0000127.
92. Gasco, A.; Fruttero, R.; Sorba, G.; Stilo, A.D.; Calvino, R. NO donors: focus on furoxan derivatives. Pure Appl. Chem., 2004, 76, 973-81.
93. Rai, G.; Sayed, A.A.; Lea, W.A.; Luecke, H.F.; Chakrapani, H.; Prast-Nielsen, S.; Jadhav, A.; Leister, W.; Shen, M.; Inglese, J.; Austin, C.P.; Keefer, L.; Arner, E.S.J.; Simeonov, A.; Maloney, D.J.; Williams, D.L.; Thomas, C.J. Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxidesas therapeutic agents against schistosomiasis. J. Med. Chem., 2009, 52, 6474-83.
94. Brachwitz, H.; Vollgraf, C. Analogs of alkyllysophospholipids: chemistry, effects on the molecular level and their consequences for normal and malignant cells. Pharmacol. Ther., 1995, 66, 39-82.
95. Eissa, M.M.; El-Azzouni, M.Z.; Amer, E.I.; Baddour, N.M. Miltefosine, a promising novel agent for schistosomiasis mansoni. Int. J. Parasitol., 2011, 41, 235-42.
96. Eissa, M.M.; Bardicy, S.E.; Tadros, M. Bioactivity of miltefosine against aquatic stages of Schistosoma mansoni, Schistosoma haematobium and their snail hosts, supported by scanning electron microscopy. Parasites Vectors, 2011, 4, 73.
97. Saudi, M.N.S.; Youssef, A.M.; Badr, M.H.; Elbayaa, R.Y.; El-azzouni, M.Z.; Mossallam, S.F.; Baddour, N.M.; Eissa, M.M. Synthesis of substituted pyrimidinedione derivatives as potential schistosomicidal agents. Lett. Drug Design Discov., 2009, 6, 268-77.
98. Spivak, A.Y.; Keiser, J.; Vargas, M.; Gubaidullin, R.R.; Nedopekina, D.A.; Shakurova, E.R.; Khalitova, R.R.; Odinokov, V.N. Synthesis and activity of new triphenylphosphonium derivatives of betulin and betulinic acid against Schistosoma mansoni in vitro and in vivo. Bioorg. Med. Chem., 2014, 22, 6297-6304.
99. Saraiva, J.; Veja, C.; Rolon, M.; Da Silva, R.; Silva, M.L.; Donate, P.M.; Bastos, J.K.; Gomez-Barrio, A.; De Albuquerque, S. In vitro and in vivo activity of lignan lactones derivatives against Trypanosoma cruzi. Parasitol. Res., 2007, 100, 791-795.
100. Pereira, A.C.; e Silva, M.L.A.; Souza, J.M.; de Laurentiz, R.S.; Rodrigues, V.; Januario, A.H.; Pauletti, P.M.; Tavares, D.C.; Da Silva Filho, A.A.; Cunha, W.R.; Bastos, J.K.; Magalhaes, L.G. In vitro and in vivo anthelmintic activity of (−)-6,6′-dinitrohinokinin against schistosomula and juvenile and adult worms of Schistosoma mansoni. Acta Tropica, 2015, 149, 195-201.
101. Ingram-Sieber, K.; Cowan, N.; Panic, G.; Vargas, M.; Mansour, N.R.; Bickle, Q.D.; Wells, T.N.C.; Spangenberg, T.; Keiser, J. Orally active antischistosomal early leads identified from the open access malaria box. PLoS Negl. Trop. Dis., 2014, 8, e2610-e2614.
102. Yao, H.Z.; Liu, F.G.; Chen, J.L.; Li, Y.; Cui, J.H.; Qiao, C.H. Antischistosomal activity of N,N′-arylurea analogs against Schistosoma japonicum. Bioorg. Med. Chem. Lett., 2016, 26, 1386-1390.
103. Dissous, C.; Grevelding, C.G. Piggy-backing the concept of cancer drugs for schistosomiasis treatment: a tangible perspective? Trends Parasitol, 2011, 27, 59-66.
104. Doenhoff, M.J.; Coles, G.C.; Pica-Mattoccia, L.; Wheatcroft-Francklow, K. Chemotherapy and drug resistance in schistosomiasis, fascioliasis and tapeworm infections. Antimicrobial Drug Resist., 2009, 629-41.
105. Pica-Mattoccia, L.; Dias, L.C.D.; Moroni, R.; Cioli, D. Schistosoma mansoni: genetic complementation analysis shows that two independent hycanthone/oxamniquine-resistant strains are mutated in the same gene. Exp. Parasitol., 1993, 77, 445-9.
106. Utzinger, J.; Keiser, J.; Shuhua, X.; Tanner, M.; Singer, B.H. Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials. Antimicrob. Agents Chemother., 2003, 47, 1487-95.
107. Bergquist, R.; Utzinger, J.; Cholett, J.; Xiao, S.H.; Weiss, N.A.; Tanner, M. Triggering of high-level resistance against Schistosoma mansoni reinfection by artemether in the mouse model. Am. J. Trop. Med. Hyg., 2004, 71, 774-7.
108. Cioli, D.; Valle, C.; Angelucci, F.; Miele, A.E. Will new antischistosomal drugs finally emerge? Trends Parasitol., 2008, 24, 379-82.
109. Balloul, J.M.; Sondermeyer, P.; Dreyer, D.; Capron, M.; Grzych, J.M.; Pierce, R.J.; Carvallo, D.; Lecocq, J.P.; Capron, A. Molecular cloning of a protective antigen of schistosomes. Nature, 1987, 326, 149-53.
110. Balloul, J.M.; Grzych, J.M.; Pierce, R.J.; Capron, A. A purified 28,000 dalton protein from Schistosoma mansoni adult worms protects rats and mice against experimental schistosomiasis. J. Immunol., 1987, 138, 3448-53.
111. Capron, A.; Capron, M.; Dombrowicz, D.; Riveau, G. Vaccine strategies against schistosomiasis: from concepts to clinical trials. Int. Arch. Allergy Immunol., 2001, 124, 9-15.
112. Zhou, Y.; Zheng, H.; Liu, F.; Hu, W.; Wang, Z.Q.; Gang, L.; Ren, S. The Schistosoma japonicum genome reveals features of host-parasite interplay. Nature, 2009, 460, 345-51.
113. Berriman, M.; Haas, B.J.; LoVerde, P.T.; Wilson, R.A.; Dillon, G.P.; Cerqueira, G.C.; Mashiyama, S.T.; Al-Lazikani, B.; Andrade, L.F.; Ashton, P.D.; Aslett, M.A.; Bartholomeu, D.C.; Blandin, G.; Caffrey, C.R.; Coghlan, A.; Coulson, R.; Day, T.A.; Delcher, A.; DeMarco, R.; Djikeng, A.; Eyre, T.; Gamble, J.A.; Ghedin, E.; Gu, Y.; Hertz-Fowler, C.; Hirai, H.; Hirai, Y.; Houston, R.; Ivens, A.; Johnston, D.A.; Lacerda, D.; Macedo, C.D.; McVeigh, P.; Ning, Z.; Oliveira, G.; Overington, J.P.; Parkhill, J.; Pertea, M.; Pierce, R.J.; Protasio, A.V.; Quail, M.A.; Rajandream, M.A.; Rogers, J.; Sajid, M.; Salzberg, S.L.; Stanke, M.; Tivey, A.R.; White, O.; Williams, D.L.; Wortman, J.; Wu, W.; Zamanian, M.; Zerlotini, A.; Fraser-Liggett, C.M.; Barrell, B.G.; El-Sayed, N.M. The genome of the blood fluke Schistosoma mansoni. Nature, 2009, 460, 352-8.
114. Young, N.D.; Jex, A.R.; Li, B.; Liu, S.P.; Yang, L.F.; Xiong, Z.J.; Li, Y.R.; Cantacessi, C.; Hall, R.S.; Xu, X.; Chen, F.Y.; Wu, X.; Zerlotini, A.; Oliveira, G.; Hofmann, A.; Zhang, G. J.; Fang, X.D.; Kang, Y.; Campbell, B.E.; Loukas, A. Whole-genome sequence of Schistosoma haematobium. Nat. Genetics, 2012, 44, 221-5.
115. O’Riordan, M.X.; Bauler, L.D.; Scott F.L.; Duckett, C.S. Inhibitor of apoptosis proteins in eukaryotic evolution and development: a model of thematic conservation. Dev. Cell, 2008, 15, 497-508.
116. Peng, J.B.; Yang, Y.P.; Feng, X.G.; Cheng, G.F.; Lin, J.J. Molecular characterizations of an inhibitor of apoptosis from Schistosoma japonicum. Parasitol. Res., 2010, 106, 967-76.
117. Rosenberg, S.H. Mammalian apoptosis in a parasitic worm. PNAS, 2011, 108, 6695-6.
118. Lee, E.F.; Clarke, O.B.; Evangelista, M.; Feng, Z.P.; Speed, T.P.; Tchoubrieva, E.B.; Strasser, A.; Kalinna, B.H.; Colman, P.M.; Fairlie, W.D. Discovery and molecular characterization of a Bcl-2-regulated cell death pathway in schistosomes. PNAS, 2011, 108, 6999-7003.
119. Abdulla, M.H.; Lim, K.C.; Sajid, M.; McKerrow, J.H.; Caffrey, C.R. Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor. PloS Med., 2007, 4, 130-8.